Mini Bioreactor Market Scope
The rise in biopharmaceutical funding for the manufacturing and development of drugs will help to fuel the mini bioreactor market around the world in the forecasted period. The mini bioreactor system is suitable for microbial and cell culture as well as stem cell applications. It is designed as a 4-fold system with up to twenty-four parallel operating bioreactors. Mini Bioreactors are used to generate more data saving time and money. There is a various application of mini bioreactors including culturing microbial cells for batch, continuous and fed-batch operations. Furthermore, the expansion of novel technology by several life sciences establishments is anticipated to drive the global mini bioreactors market.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Mini Bioreactor market throughout the predicted period.
Thermo Fisher Scientific (United States), Merck Millipore (Germany), Danaher (United States), GE Healthcare (United States), Sartorius Stedim Biotech (France), Eppendorf AG (Germany), Pierre Guerin (DCI-Biolafitte) (France), Praj Hipurity Systems (India) and Bioengineering AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Infors HT (Switzerland) and Applikon Biotechnology (Netherlands).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Segmentation Overview
The study have segmented the market of Global Mini Bioreactor market by Type (250 ml, 500 ml and 1000 ml), by Application (Biopharmaceutical Companies, CROs, Academic and Research Institutes and Others) and Region with country level break-up.
On the basis of geography, the market of Mini Bioreactor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In 2018, Getinge (Sweden) acquired Applikon Biotechnology (Netherlands), a leading provider of bioreactor systems. This acquisition will strengthen Getinge’s Life Science business segment in the single-use bioreactors market.
In 2019, Pall Corporation (US) entered into a partnership with Freeline (UK) to implement its iCELLis bioreactor system in the Freeline’s adeno-associated virus (AAV) manufacturing platform. This partnership aims to achieve commercial scale and quality production of AAV gene therapy vectors.
Market Trend
- Technological Advancements in Mini Bioreactor
Market Drivers
- Rising Biopharmaceuticals and Biologics Companies
- Growing Focus on Orphan Drugs Development
- Increasing Demand for Personalized Medicines
Opportunities
- Increasing Biopharmaceutical R&D
- Growing Biologics Market
- Growth in the Emerging Countries
Restraints
- Regulatory concerns related to Mini Bioreactor
- Issues related to Leachables and Extractables
Challenges
- Standardization of Mini Bioreactor Designs
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Mini Bioreactor Manufacturers, Venture Capitalists, Government Regulatory, Research Organizations and End-Use Industry